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Background: Testicular cancer (TC) is the most common cancer in the 25–40 age group, with
peak morbidity at around 30 years of age. It is a period of highest productivity, when sexual
sphere is an important aspect of life. The disease, invasive treatment and its consequences
interfere with this sphere.
Aim: The aim of this paper was to review the most recent studies on the sexual functioning
of  patients treated for testicular cancer and their partners published in English language
scientiﬁc journals in the period of 1989–2010.
Results: Numerous studies report that men cured from testicular cancer are at risk of sexual
disorders. Agents of psychological nature play an important role in the occurrence and
persistence of sexual dysfunctions. Being in permanent relationship is a protective factor,
while single persons are marked with particular predisposition to such dysfunctions. Sexual
and  marital satisfaction of TC survivors and their partners are mutually correlated.
Conclusion: With a growing number of TC survivors, a thorough investigation is required intotheir  sexuality, both in an individual and dyadic dimension, so as to improve the quality of
life  of the affected young men, who take on their new social and professional roles in the
period of highest reproductiveness.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.1.  Background
Testicular cancer, although relatively rarely diagnosed, is the
most prevalent type of cancer in men  between 25 and 40 years
of age. It is a period of highest productivity, when sexual part-
ners are chosen, families settled, professional careers started,1a time when sexual activity becomes an important aspect of
life. Due to the nature of the involved organ, the cancer inter-
feres with a broadly understood sexuality. It affects the organ
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which is associated with masculinity. A surgical intervention,
irradiation or chemotherapy entail short- or long-term side
effects that undermine one’s sense of masculinity. This may
lead to a decline of self-esteem and be reﬂected in a variety of
sexual disorders.2
The disease affects the whole of family life. A note should
be taken of psychological burden carried by the patient’s part-
ner. Mutuality of the relationship indicates that any disruption
of an individual mental and sexual balance is reﬂected in the
functioning and well being of the partner.kie Centrum Onkologii, im. Marii Skłodowskiej-Curie, ul. Garbary
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Table 1 – Summary of study results.
1. Men who survived testicular cancer are at risk of sexual
disorders7,8,10–13,15–18
2. TC survivors who did not have a permanent relationship at
the time of diagnosis and treatment are particularly
exposed to various sexual dysfunctions14,22
3. Younger age is a protective factor8,18
4. Most sexual disorders are short lived11,14–17
5. The most sexual disorders are caused by chemotherapy
and RLND7,12,20
6. Ejaculation disorder is the most prevalent sexual
dysfunction15,17,18
7. TC treatment is often followed by a decline in sexual
activity8,12,13
8. Ejaculation disorder is the only condition speciﬁcally
related to RLND7,11,15–17 or, in our study, to chemotherapy18
9. Psychological factors play a role in emergence and
persistence of sexual dysfunctions10,12,13,15,17,22
10. Sexual satisfaction is relatively high despite sexual
8,12,13,15,18
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Fig. 1 – Seligman’s layer-based sexuality model.dysfunctions
Source: own study.
.  Aim
he aim of this paper was to review the most recent studies on
he sexual functioning of patients treated for testicular can-
er and their partners published in English language scientiﬁc
ournals in the period of 1989–2010.
.  Materials  and  methods
he paper systematises study results, identiﬁes main research
irections and indicates issues that require further investiga-
ion (Table 1). The scientiﬁc articles were found in the PubMed
rowser and the web by means of the following inputs: testicu-
ar cancer + sexual function, testicular cancer + sexual functioning,
esticular cancer + sexual satisfaction, testicular cancer + marital
atisfaction, testicular cancer + sexual dysfunctions. We  also used
eferences given in the journals.
.  Treatment  of  testicular  cancer
reatment of testicular cancer is a multidisciplinary process.
t involves the removal of the testicle with tumour, other-
ise known as orchiectomy. Further treatment depends on the
ype and clinical stage of cancer. Good-prognosis nonsemino-
as  are observed or treated with dissection of retroperitoneal
ymph nodes. In the case of dissemination, chemotherapy is
pplied (mainly according to the BEP protocol) with possible
issection of residual lesions. In the case of metastatic semi-
omas, a standard treatment involves chemotherapy with
ossible radiation therapy of the remaining lesions. The use
f Retroperitoneal Lymph Node Dissection (RLND) is consid-
red after completion of the cisplatin-based therapy. Around
0–30% of TC patients show no response to standard treat-
ent modalities. They require more  aggressive high-dosehemotherapy, including transplantation of marrow stem
ells. Treatment is followed by many  years of surveillance
ith a view to diagnose any possible recurrence at the earliestSource:  based on Seligman (2003).
possible clinical stage. The highest risk of recurrence is
observed within the ﬁrst year after treatment.3
Cisplatin-based chemotherapy, introduced in the 1980s,
caused recovery rates to rise up to 90%, offering chance of
recovery even to patients with extensive metastases. How-
ever, chemotherapy is an aggressive method of treatment.
Patients may be affected with side effects whose occurrence
and intensity depend on dose and individual predispositions.
Frequently reported side effects are: (1) nausea and vomiting;
(2) metallic taste in the mouth; (3) nose and gum bleed-
ing, bruising; (4) fatigue and reduction in physical activity;
(5) decrease of erythrocytes; (6) loss of hair; (7) oral ulcera-
tion; (8) fever and shivering; (9) hearing and balance disorders.
Other complications include secondary cancers and damage
to the lung parenchyma. BEP protocol chemotherapy may also
damage the gonads and cause a temporary or permanent
infertility. Adverse effects of the disease and its treatment on
sexuality are estimated to occur in 15–60% patients. Most of
these symptoms disappear soon after treatment and can be
mitigated with a wide range of pharmaceuticals. Long-lasting
effects include metabolic disorders, circulatory disturbances,
damage to peripheral nerves, and infertility. This is the price
that has to be paid for high efﬁcacy of the therapy in terms of
health and survival.
5.  Male  sexuality  –  health  and  pathology
Sexuality is an immanent trait of every human. It is univer-
sal and dynamic in nature, as it changes with an individual’s
growth and experience. A complex structure of sexuality is
shown in Seligman’s model (Fig. 1). It distinguishes ﬁve lay-
ers: sexual identity; sexual orientation; sexual preferences;
sex role; and sexual performance.
The order of the layers suggest a growing importance of
psychological factors and declining importance of biological
ones in determining particular levels. The model has signif-
icant practical implications as it indicates predisposition to
change of particular structures and efﬁcacy of medical and
psychological impacts. The deeper the structure and the larger
share of biological factors in its functioning, the stronger resis-
tance to change and the more  signiﬁcant role of medical
rather than psychological interventions. And the other way
round: more  superﬁcial layers – determined, in most part, by
56  reports of practical oncology and ra
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Fig. 2 – Male sexual response reaction cycle according to
Masters and Johnson’s model.
1 Toxicity of chemotherapy manifests itself, among other
symptoms, by vascular and neurological complications. The
former takes the form of Raynaud’s syndrome, i.e. peripheral
ischemia causing discolouration and ﬁnger and toe painsSource:  based on Masters and Johnson (1975).
psychological agents – offer a greater chance for a change to
be induced by psychological methods.4
Testicular cancer may lead to changes in the area of sexual
expression when treatment is accompanied by disorders in
physiologically and psychologically conditioned sexual func-
tioning, and that of sex roles when extensive side effects
restrict the activity which is socially and culturally attributed
to men.
Male sexual expression and sex roles involve the following
important aspects: (1) sense of masculinity; (2) sense of being
attractive for the opposite gender; (3) sexual drive; (4) phases
of sexual response cycle (arousal, erection, ejaculation and cli-
max  [Fig. 2]; (5) sexual satisfaction.5 Each of them may feature
dysfunctions as biological and psychological consequences of
cancer diagnosis and treatment.
Correct male sexual expression is conditioned by the
anatomical structure and functioning of the sexual organs, the
functioning of the circulatory and nervous systems, hormonal
balance and psychological factors.6
6.  Sexual  functioning  of  testicular  cancer
survivors  –  review  of  English  language  literature
6.1.  Testicular  cancer  survivors  vs.  whole  population
Retrospective study by Rieker et al.7 indicated that testic-
ular cancer survivors experienced a more  severe distress,
as compared to the total population, with regard to objec-
tive dimension of sexual functioning: ejaculation disorders
(24% vs. 1%), erection disorders (10% vs. 3%), while exhibiting
no signiﬁcant differences in subjective dimension of sexual-
ity: sexual desire (11% vs. 8%) and sexual satisfaction (12%
vs. 13%). Higher risk of infertility and sexual dysfunctions
occurred in men  after chemotherapy and RLND. This study
gave rise to a series of investigations into TC survivors’ sexual
functioning with different treatment modalities.
6.2.  Radiation  therapy  and  sexuality  of  seminoma
patients
Tinkler et al.8 analysed sexuality of seminoma patients treated
with radiation therapy. Compared to a control group, they
showed reduced libido, difﬁculties in maintaining erection
(p = 0.0013), lower intensity of orgasm, and reduction of semen.diotherapy 1 7 ( 2 0 1 2 ) 54–62
No differences in ejaculation and sexual satisfaction were
found, which is interesting considering other disorders in
this area. This may be accounted for by a reduced libido
in that group. The study found a signiﬁcant difference in
the frequency of sexual intercourses (p = 0.03), interest in sex
(p = 0.005), ability to maintain erection (p = 0.005) and amount
of semen (p = 0.01) in patients aged below 35 years, as com-
pared to older ones, with younger patients performing better.
Age is then a factor of signiﬁcant importance to sexual func-
tioning both in healthy and diseased population; it worsens
the side effects of treatment.
6.3. Chemotherapy  and  sexual  functioning
The toxicity of chemotherapy depends on the dose of cysto-
statics. Larger amounts of medicines and longer treatment
is associated with higher probability of disorders in various
bodily functions. Treatment involving two courses of adju-
vant chemotherapy (BEP or PVB protocols) does not often
lead to major or permanent sexual dysfunctions.9 However,
chemotherapy with larger number of courses and higher doses
of medicines carries the risk of sexual disorders in patients
with testicular cancer of higher clinical stage. Van Basten10
reported reduced libido, decline in sexual arousal, erection
and ejaculation disorders, lower intensity of orgasm and
lower volume of semen in patients treated with chemother-
apy, as compared to patients managed with orchiectomy
alone. Absence of ejaculation was observed to be the only
dysfunction related to a speciﬁc treatment modality, i.e. post-
chemotherapy resection of retroperitoneal residual tumour
masses (RRRTM). This applied to as much as 25.6% of the
group.
6.3.1.  Chemotherapy  with  regard  to  sexual  dysfunctions
and treatment-induced  angiopathy  and  neuropathy
The same study10 posed a hypothesis of angiopathic back-
ground of Raynaud’s phenomenon1 and lack of erection.
Raynaud’s phenomenon was found in 32.7% of the chemother-
apy group. Much  more  patients affected with that condition
reported erection problems (28.85%) than did those not
affected (8.4%; p < 0.05). The hypothesis was veriﬁed by the
same research team in a later longitudinal study on 21 men.
Ten of them had undergone chemotherapy according to the
BEP protocol (4 courses), the other 11, after orchiectomy alone,
made up a control group. Results of Doppler ultrasound did
not show any differences between both groups in terms of
blood ﬂow in the corpora cavernosa.11 With this hypothesis
unconﬁrmed, other organic and psychological factors behind
TC survivors’ dysfunctions had to be looked for.induced by low temperature or strong emotions, followed by the
sensation of heat and redness. The latter, peripheral paresthesia,
involves a damage to peripheral nerves in the region of the palms
and  feet causing numbness, tingling or pain.
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.  Sexual  functioning  with  regard  to
arious  treatment  modalities  –  psychological
actors
onker-Pool et al. pointed at the direct and indirect role
f psychological factors in the occurrence and intensity of
exual dysfunctions in testicular cancer survivors.12 They ana-
ysed the sexual function in the context of various treatment
odalities. They found that 22.5% of patients treated with
rchiectomy experienced at least one type of sexual disorders,
ven though orchiectomy is the least invasive of all testicular
ancer treatment procedures. A relatively large proportion of
atients after radiotherapy reported decline in libido and sex-
al activity (22% each), but this was not likely to be caused
y a low level of testosterone. Furthermore, erection disor-
ers occurring in only 14.5% of patients imply that a massive
amage to coronary vessels, that is organic factors, should
e excluded. A statistically signiﬁcant proportion of testicular
ancer survivors treated with chemotherapy showed reduced
ibido (29.5%) and less intensive orgasm (28.5%). Surprisingly,
 decline in libido, orgasm intensity and sexual activity in
atients treated with both chemotherapy and RRRTM was
ound to be smaller than in those subjected to chemotherapy
lone (a statistically insigniﬁcant difference). This can hardly
e accounted for by biological and organic effects of treatment.
t is psychological agents that might be of great relevance here.
Interestingly, despite sexual function being restricted, the
ecline in sexual satisfaction is very limited12 or none at all,
s compared to the total population.13 Faced with a heavy
motional distress of a life-threatening disease, patients may
eorient their priorities and values and thus change their per-
eption of the disease. This may also be explained by the
ecline in libido and more  intimacy in a relationship.
The study by Fegg et al.13 indicates psychological implica-
ions of the disease and its treatment, such as anxiety over a
ailure to satisfy one’s partner (22% of respondents) or inhi-
itions towards one’s partner (9.6%), which may determine
exual functioning, along with physical conditions. Notably,
hanges in sexual functioning occurred immediately after
iagnosis in 14.4% of patients; at the beginning of treatment in
3.8%; and after treatment in 65.1%, thus further conﬁrming
he importance of mental factors.
.1. New  research  direction:  sexual  dysfunction  risk
actors in  testicular  cancer  survivors
ongitudinal study on sexual functioning of testicular can-
er patients treated with chemotherapy during the ﬁrst year
ollowing orchiectomy was conducted by Tuinman et al.14 It
howed that marital status (single or committed) is a risk fac-
or for sexual dysfunctions. The men  who  were single at the
ime of diagnosis reported more  sexual problems than those
n permanent relationships, except for sexual desire. Commit-
ed partners at the time of diagnosis experienced increased
ntimacy in their relationships, likely to act as a buffer protect-
ng them against adverse emotions and consequences of the
isease. Singles were deprived of that protective mechanism.
oreover, they could feel more  afraid of infertility. The fear
f infertility negatively affects sexual functioning and raisesiotherapy 1 7 ( 2 0 1 2 ) 54–62 57
concerns over future intimate relations. It is also worth not-
ing that singles have fewer sexual intercourses with more
partners, hence different aspects of their sexuality are more
difﬁcult to evaluate. The lack or lower frequency of sexual
activity may lead to reduced performance and artefacts.
Symptoms of clinical depression after chemotherapy were
substantially more  often observed in singles than committed
partners. Depressive symptoms were related to erectile dis-
orders, lower sexual satisfaction and overall deterioration of
sexual functioning three months after orchiectomy. One year
after testicle removal, depressive symptoms did not show any
predictive value for sexual dysfunctions. Thus, they can be
claimed to represent a risk factor only within several months
following diagnosis.
8.  Valuable  information  –  meta-analyses
The results of meta-analysis made by Jonker-Pool15 to exam-
ine sexual functioning for various treatment modalities were
as follows:
• ejaculation dysfunctions – most prevalent type of sexual
disorders – were linked with removal of retroperitoneal
lymph nodes more  than with any other medical procedure;
• erection dysfunctions, least prevalent of all disorders, were
associated with radiotherapy;
• the occurrence of ejaculation and erection problems
induced by objective physiological factors were mostly
related to treatment modalities; psychological factors
played a signiﬁcant role for dysfunctions of subjective
nature: decline in libido, reduction of orgasm intensity, sex-
ual activity and satisfaction;
• sexual dissatisfaction was relatively low in relation to the
overall number of sexual disorders.
Those results were reconﬁrmed by meta-analyses made by
Rosendal16 and Nazareth,17 suggesting that testicular cancer
patients can experience a variety of sexual, mostly short-term
dysfunctions of organic or psychological origin.
The meta-analyses15–17 revealed a diversity in study results
in terms for variables used, treatment modalities, proportion
of sexual dysfunctions (literature reports the loss of libido
ranging from 2 to 69%, and ejaculation disorders ranging from
17 to 100%), as well as some methodological weaknesses:
lack of control groups or use of unstandardised tools for vari-
able measurements. Only few studies were actually suited for
comparison.17 For that reason, results of the meta-analyses
should be approached with a lot of caution.
8.1.  Is  the  sexual  function  compromised  in  testicular
cancer  survivors?  –  references  to  meta-analyses
The meta-analyses were responded to by a cross-sectional
study18 on a large sample of 1084 long-term survivors, compar-
ing results with a control group and using a standardised tool
for measuring the sexual function. It conﬁrmed the results of
the meta-analyses, i.e. the occurrence of ejaculation disorders
in testicular cancer survivors and subjective aspects of sexu-
ality independent from treatment modality: desire and sexual
nd ra58  reports of practical oncology a
satisfaction, as well as a relatively high rate of sexual satis-
faction in relation to the rate of sexual dysfunction. At the
same time, some differences in relation to the Jonker-Pool’s
study15 were revealed: erection, the physiological sexual func-
tion, proved to be unaffected by treatment, while ejaculation
disorder was found to be the only dysfunction dependent on a
speciﬁc type of treatment, that is with chemotherapy, but not
RLND. This may be due to the modiﬁcation of RLND that has
diminished the invasiveness of the procedure since the late
1980s.
It is worth noting that worse sexual functioning was cor-
related with neurotoxical side effects of (moderate), chronic
post-treatment fatigue (signiﬁcant), high anxiety according
to the Hospital Anxiety and Depression Scale (HADS) (sig-
niﬁcant), lack of physical activity (moderate). Multivariate
analysis showed older age, lack of permanent partner and
elevated anxiety in persons affected with sexual problems.
Ejaculation dysfunctions were in turn correlated with the
absence of a permanent partner, chemotherapy and neuro-
toxicity of treatment.
9.  Adolescents  and  young  adults  with
testicular  cancer  –  developmental  approach
Carpentier,19 after having reviewed 37 reports from 1980 to
2009, pointed at the deﬁciency of studies related to adoles-
cents and young adults with diagnosed testicular cancer, even
though the disease has its peak occurrence in the years of early
adulthood, applying also to the age of adolescence. She pro-
posed a developmental approach focused on developmental
functions speciﬁc to those life stages, whose natural devel-
opment can be disturbed by the disease and treatment. She
also proposed a hypothesis that cancer of the testicle in ado-
lescence and its accompanying changes of body self-image
may disturb the natural emergence of sexual identity and con-
sequent entry into sexual and romantic relationships. She
stressed that being single at the time when the disease is
recognised causes a speciﬁc vulnerability, which persists after
the therapy is completed despite developing a relationship.
The author highlighted the need to further explore the issue
in the context of developmental functions of those age groups.
10.  Sexual  functioning  of  a  couple  following
testicular  cancer  treatment  –  relational
approach
10.1. Long-term  effects  of  testicular  cancer  treatment  –
perspective  of  a  couple
The study by Gritz20 was the ﬁrst one to look at the couple’s
sexual functioning following testicular cancer treatment. She
initiated the relational approach to this research area. The
study was of a cross-sectional design; it involved 34 couples,
who  had been married from the diagnosis to the study onset,
meaning they had gone together through the cancer diagno-
sis and treatment processes. Testicular cancer treatment had
a signiﬁcant impact on the men’s body self-image and sense
of being attractive. Although most of the patients (64.7%) anddiotherapy 1 7 ( 2 0 1 2 ) 54–62
their partners (88.2%) did not report any loss of attractive-
ness following treatment, more  men  (35.3%) felt less attractive
than perceived by their partners (11.8%). The loss of attractive-
ness in some patients was of a long-term nature (23.5%), while
the women perceived it as a short-term effect (11.8%), if any.
This pattern of perceived attractiveness applied to all kinds of
treatment modalities, except chemotherapy. Cisplatin-based
treatment reduced patients’ attractiveness for 70% of their
female partners, that is more  than in their own perception
(60%). Researchers suggest that women support their partners
by protecting them from their own reactions in the period of
treatment and afterwards.
Sexual dysfunctions were mostly short lived, except for
ejaculation problems. Notably, the change in the level of sexual
satisfaction (47.1% of husbands and 54.9% of wives) meant a
reduced satisfaction in 29.4% of the men  and an increased sat-
isfaction in 47.1% of the women. Nearly a half of the patients
(47%) and 50% of their partners reported no changes in the
frequency of sexual contacts. The remaining majority experi-
enced a drop (38.2% of the men  and 32.4% of the women) rather
than rise in the number of sexual contacts. The frequency of
sexual intercourses correlated positively with sexual satisfac-
tion. Chemotherapy and radiotherapy distorted the couples’
sexual functioning in a greater extent. The female partners
more  often avoided sexual intercourse after treatment (36.4%
for orchiectomy, 23.1% for RLND, 50% for chemotherapy and
37.5% for radiation therapy) than perceived by their male
partners (12.1% for orchiectomy, 23.1% for RLND, 10% for
chemotherapy and 25% radiation therapy), which again exem-
pliﬁes wives’ protective attitude. The avoidance tendency was
a short-term process.
The study by Gritz20 and Hannah21 on the same sample
of patients demonstrated that cancer-induced disturbances
in sexual and marital relationships are of minor and tempo-
rary nature. Most of the couples were able to go through the
treatment and disease period, strengthening their mutual ties,
trust, understanding, commitment and intimacy. A minority
experienced more  serious and long lasting problems.
10.2.  Couples  in  permanent  relationships  established
before  and  after  treatment  –  signiﬁcant  differences
Tuinman22 made a distinction between permanent rela-
tionships established before and after treatment, indicating
differences between the two in terms of sexual and mari-
tal functioning. The difference applied only to male partners
who had a relationship at the start of treatment. They experi-
enced more  sexual satisfaction than the men  from the other
group. Partners from both groups reported less sexual satis-
faction than the control group. The results suggest a negative
impact on sexual relationship in all persons affected by the
disease (only female partners in relationships developed after
treatment did not differ in terms of sexual satisfaction from
the reference group). Of couples established before diagnosis,
marital problems of clinical relevance were found in 12% of the
men and as much as 22% of their spouses. A reverse tendency
was observed in the couples who developed their relation-
ships after treatment. A signiﬁcantly more  men  (25%) than
women (18%) experienced clinically relevant marital prob-
lems. The results endorse Carpentier’s thesis19 of speciﬁc
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redispositions to sexual dysfunction in patients who are sin-
le at the time of treatment. There is a need for further study
n men  developing their intimate relationships after comple-
ion of testicular cancer treatment to identify potential threats
nd chances for their future partners.
1.  Conclusion
he review of the English language literature reveals the com-
lexity of the issue of men’s sexual functioning after testicular
ancer treatment. Sexuality, originally regarded as a unidi-
ensional concept, has developed into a multidimensional
ystemic perspective. Various factors are analysed: biological,
sychological and sociodemographic. Their constellations are
xamined to identify risk and protective factors for sexual dis-
rders in TC survivors. Subgroups of men  are distinguished
nd compared in respect of various development stages, their
asks and cancer-related threats for development.
Many  of the described studies are limited by their method-
logical weaknesses involving the use of unstandardised tools
or measuring sexual functioning7–13 and lack of control
roups.9,13 Only few apply standardised questionnaires14,18,22
nd/or employ reference groups.1,7,8,10–12,14,22 Prospective
tudies are still in short supply,18,22 with cross-sectional inves-
igations representing a vast majority. The above mentioned
ethodological drawbacks compromise the value and impede
omparison of study results. Another difﬁculty lies in high
iversity of studied groups as regards culture and sexual-
ty, varied therapy standards and differences in availability
f medical procedures. However, the methodological correct-
ess of research grows with the level of complexity, delivering
seful scientiﬁc evidence.iotherapy 1 7 ( 2 0 1 2 ) 54–62 59
12.  Potential  directions  of  further  study
The review of literature stresses the need for further study of
sexual functioning in testicular cancer survivors in a multi-
dimensional and systemic perspective, with due care taken
of methodological aspects (standardised research tools, con-
trol group, prospective study, randomised selection of study
subjects).
Potential directions of further research include:
• functioning of young adults and adolescents with testicular
cancer in the context of developmental functions speciﬁc
for this stage of life – developmental perspective;
• developmental approach to effects of testicular cancer and
its treatment for men  at different developmental stages;
• testicular cancer in homosexual couples;
• cultural background of sexual disorders (type, intensity);
• risk and protective factors before occurrence of sexual dys-
functions in a group of testicular cancer patients seen from
a holistic perspective;
• short- and long-term effects of treatment and their back-
ground – longitudinal studies;
• mental and sexual functioning of TC survivors’ partners;
• impact of a psychological intervention, social support23 and
music therapy24 on the quality of life and sexual life in tes-
ticular cancer.whereas its usefulness and a growing number of survivals25
indicate practical beneﬁts of new scientiﬁc ﬁndings.
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Appendix  A.
The study The study
design
Sample
characteristics
Control sample Instruments
used
Standardised
sexual
function
questionnaire
Rieker et al. (1989)
USA
Cross  sectional 223 men;
RT – 32%
CT – 9%
RLND – 17%, CT + RLND –
33%;
RT + CT/RT + RLND – 9%
Yes,
120 men
Proﬁle of Mood States
(POMS);
an abbreviated form of the
Cancer Patient Behavior
Scale (CPBS)
Concealing Emotions Scale
(CES)
Self-Report Questionnaire
No,
Self-Report Questionnaire
designed speciﬁcally for the
study
Tinkler et al. (1992)
Great Britain
Cross sectional 155 men;
ORCH – 18 men
ORCH + RT – 137 men
121  men Sexual function
questionnaire-design
speciﬁcally for the study
No,
sexual function
questionnaire-designed
speciﬁcally for the study
Böhlen et al. (2001)
Switzerland
Cross  sectional 49 men;
CT – 2 cycles – 100%
No Sexual  function
questionnaire-design
speciﬁcally for the study
No,
sexual function
questionnaire-designed
speciﬁcally for the study
Van Basten (1997)
The Netherlands
Cross  sectional 215 men;
ORCH – 26%
CT – 19.6%
CT + RRRTM – 54.4%
Yes;
the men treated with
orchidectomy and
surveillance as reference
group
A  self-report
inventory-designed on
items of the Intimate Bodily
Contact Scale (IBSC) of
Vennix and Groningen
Arousability Scale (GAS)
questionnaires
No,
a self-report inventory
designed speciﬁcally for the
study
Van Basten (1999)
The Netherlands
Longitudinal 21 men;
ORCH – 11 men
CT – 10 men. (4 cycles of
BEP)
Yes;
the  men treated with
orchidectomy and
surveillance as reference
group
A  self-report
inventory-designed on
items of the Intimate Bodily
Contact Scale (IBSC) of
Vennix and Groningen
Arousability Scale (GAS)
questionnaires;
Visual Erotic Stimulation
Test (VES)
No,
a  self-report inventory
designed speciﬁcally for the
study
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The study The study
design
Sample
characteristics
Control sample Instruments
used
Standardised
sexual
function
questionnaire
Jonker-Pool (1997)
The Netherlands
Cross  sectional 264 men;
ORCH – 22.5%
RT – 15.5%
CT – 16%
CT + RRRTM – 46%
Yes;
the men treated with
orchidectomy and
surveillance as reference
group
A
questionnaire designed
speciﬁcally for the study
No,
a  questionnaire designed
speciﬁcally for the study
Fegg (2003)
Germany
Cross  sectional 341 men;
ORCH – 19%
CT – 24.6%
CT + RRRTM – 56.4%
No  Questions on Life
satisfaction (QLS);
No,
a  Self-Report Questionnaire
designed
speciﬁcally for the study
Tuinman et al. (2010)
The Netherlands
Longitudinal 93 men;
ORCH – 26%
CT – 44%
CT + RRRTM – 30%
Yes,
109 men
International Index of
Erectile Function (IIEF);
The Center for
Epidemiological
Studies-Depresion Scale
(CES-D)
Yes,
International Index of
Erectile Function – IIEF
Dahl et al. (2007)
Norway
Cross sectional 1084 men;
ORCH – 9%
RLND – 13%
RT – 46%
CT/CT + RRRTM – 32%
Yes,
the representative sample
of Norwegian male
population (2100 males in
2004 and 1394 in 2005)
The Hospital Anxiety and
Depression Scale (HADS);
The Fatique Questionnaire
(FQ);
The Brief Male Sexual
Function Inventory – BSFI
Yes;
The Brief Male Sexual
Function Inventory – BSFI
Gritz et al. (1989)
USA
Cross sectional 34 married couples No The structured
interview-seven
psychometric instruments
administered as a part of
the interview
No
Tuinman et al. (2005)
The Netherlands
Cross  sectional 259 couples (relationships
established before (85%)
and after treatment (15%)
No The  Dutch version of the
Maudsley Marital
Questionnaire (MMQ)
Yes,
The Dutch version of the
Maudsley Marital
Questionnaire (MMQ)
ORCH, orchidectomy; CT, chemotherapy; RT, radiotherapy; RLND, Retroperitoneal Lymph Node Dissection; RRRTM, resection of retroperitoneal residual tumour masses.
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